title: Epigenetic biomarkers in prostate cancer: Current and future uses.
abstract: Epigenome alterations are characteristic of nearly all human malignancies and include changes in DNA methylation, histone modifications and microRNAs (miRNAs). However, what induces these epigenetic alterations in cancer is largely unknown and their mechanistic role in prostate tumorigenesis is just beginning to be evaluated. Identification of the epigenetic modifications involved in the development and progression of prostate cancer will not only identify novel therapeutic targets but also prognostic and diagnostic markers. This review will focus on the use of epigenetic modifications as biomarkers for prostate cancer.
authors.affiliation: Cancer Research Program, Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia.
authors.forename: Karen
authors.initials: K
authors.lastname: Chiam
authors.forename: Carmela
authors.initials: C
authors.lastname: Ricciardelli
authors.forename: Tina
authors.initials: T
authors.lastname: Bianco-Miotto
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D019175:DNA Methylation; D044127:Epigenesis, Genetic; D015972:Gene Expression Regulation, Neoplastic; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006657:Histones / Q000378:metabolism; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics; D010641:Phenotype; D011237:Predictive Value of Tests; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor; D006657:Histones; D035683:MicroRNAs